Olga Evgenevna Voronko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Olga Evgenevna Voronko has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Margarita Pavlovna Markina
Koltzov Institute of Developmental Biology of Russian Academy of Sciences, Moscow 119334, Russia
2 shared publications - Vagif Ali Oglu Gasanov
Koltzov Institute of Developmental Biology of Russian Academy of Sciences, Moscow 119334, Russia
2 shared publications - Andrey Gennadievich Popandopulo
Laboratory of Cell and Tissue Cultivation, Federal State Budgetary Institution “V.K. Gusak Institute of Emergency and Reconstructive Surgery” of the Ministry of Health of the Russian Federation, Donetsk 283045, Russia
1 shared publication - Arthur Anatolievich Lee
Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, 119334 Moscow, Russia
1 shared publication - Dmitry Alekseevich Filimonov
Federal State Budgetary Institution “V.K. Gusak Institute of Emergency and Reconstructive Surgery” of the Ministry of Health of the Russian Federation, Donetsk 283045, Russia
1 shared publication - Dmitry Alexandrovich Kashirskikh
Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, 119334 Moscow, Russia
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1131
Probiotics in the Treatment of Infected Wounds: Current State and Delivery Technologies
Wound infections remain a challenging problem in modern medicine amid the growing antimicrobial resistance of pathogens. Topical probiotics, primarily representatives of the genera Lactobacillus and Bifidobacterium, are considered as a promising alternative to traditional antibiotics due to their ability to suppress pathogen growth, disrupt biofilms, modulate immune response, stimulate tissue regeneration, and restore the wound microbiome. Despite encouraging preclinical data, the clinical application of live probiotics is constrained by technological barriers related to bacterial instability, the need to maintain their viability, and the risk of systemic dissemination. This review systematizes the current understanding of the mechanisms of action of probiotics in wound infection, particularly for topical application, and analyzes their delivery technologies, including hydrogels, microparticles, nanofibers, and hybrid systems. Preclinical and clinical studies, challenges in clinical translation, and promising directions for future research are also discussed. In conclusion, the combination of topical live probiotics with hybrid delivery systems has demonstrated encouraging efficacy in preclinical settings; however, its translation into clinical trials will require standardization of dosages and delivery protocols, as well as further improvement of safety profiles.
- 12 November 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1131
Open AccessProbiotics in the Treatment of Infected Wounds: Current State and Delivery Technologies
Wound infections remain a challenging problem in modern medicine amid the growing antimicrobial resistance of pathogens. Topical probiotics, primarily representatives of the genera Lactobacillus and Bifidobacterium, are considered as a promising alternative to traditional antibiotics due to their ability to suppress pathogen growth, disrupt biofilms, modulate immune response, stimulate tissue regeneration, and restore the wound microbiome. Despite encouraging preclinical data, the clinical application of live probiotics is constrained by technological barriers related to bacterial instability, the need to maintain their viability, and the risk of systemic dissemination. This review systematizes the current understanding of the mechanisms of action of probiotics in wound infection, particularly for topical application, and analyzes their delivery technologies, including hydrogels, microparticles, nanofibers, and hybrid systems. Preclinical and clinical studies, challenges in clinical translation, and promising directions for future research are also discussed. In conclusion, the combination of topical live probiotics with hybrid delivery systems has demonstrated encouraging efficacy in preclinical settings; however, its translation into clinical trials will require standardization of dosages and delivery protocols, as well as further improvement of safety profiles.
- Open Access
- 19 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8351
Apoptosis Modulation by LL-37: From Mitochondrial Cell Death to Prosurvival Signaling
This review summarizes current knowledge on the role of human cathelicidin LL-37 in the regulation of apoptosis. LL-37 can modulate programmed cell death pathways, exerting either proapoptotic or antiapoptotic effects depending on various factors, such as cell type and peptide concentration. Data on LL-37 derivatives and their involvement in apoptosis are also discussed. Understanding the molecular mechanisms underlying LL-37 regulation of apoptosis is necessary to expand the therapeutic potential of this peptide in various pathological conditions, including cancer.
- 19 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8351
Open AccessApoptosis Modulation by LL-37: From Mitochondrial Cell Death to Prosurvival Signaling
This review summarizes current knowledge on the role of human cathelicidin LL-37 in the regulation of apoptosis. LL-37 can modulate programmed cell death pathways, exerting either proapoptotic or antiapoptotic effects depending on various factors, such as cell type and peptide concentration. Data on LL-37 derivatives and their involvement in apoptosis are also discussed. Understanding the molecular mechanisms underlying LL-37 regulation of apoptosis is necessary to expand the therapeutic potential of this peptide in various pathological conditions, including cancer.